3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
111
Neoplasms, Plasma Cell
50
Lymphoma, Non-Hodgkin
39
Lymphoma
35
Hodgkin Disease
35
Myelodysplastic Syndromes
32
Leukemia, Lymphocytic, Chronic, B-Cell
32
Leukemia
32
Precursor Cell Lymphoblastic Leukemia-Lymphoma
31
Lymphoma, Follicular
29
Lymphoma, Mantle-Cell
28
Lymphoma, Large-Cell, Immunoblastic
28
Burkitt Lymphoma
28
Lymphoma, Large B-Cell, Diffuse
27
Lymphoma, B-Cell, Marginal Zone
27
Leukemia, Myeloid, Acute
23
Myeloproliferative Disorders
21
Immunoglobulin Light-chain Amyloidosis
18
Leukemia, Myeloid, Chronic-Phase
17
Dendritic Cell Sarcoma, Interdigitating
17
Recurrence
15
Primary Myelofibrosis
14
Leukemia, Myelomonocytic, Chronic
14
Congenital Abnormalities
14
Blast Crisis
14
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
13
Leukemia, Myeloid, Accelerated Phase
13
Myelodysplastic-Myeloproliferative Diseases
12
Lymphoma, T-Cell, Cutaneous
10
Graft vs Host Disease
10
Interventions
Lenalidomide
4
Dexamethasone
4
Bortezomib
3
pomalidomide
2
Cyclophosphamide
2
ricolinostat
1
Zoledronic Acid
1
Vitamin D
1
Transplantation, Autologous
1
Melphalan
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Calcium Dobesilate
1
Calcium
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Filgrastim
×
Plasma cell
×
Clear all
NCT02043847
2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1
Completed
12 enrolled
12 charts